Smith & Nephew plc (SNN US)
SNN US$30.12
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 30.12
- Change
- ▲ 0.02 (0.07)
- Bid / Ask
- 30.13 - 30.14
- Volume
- 214,523
- Turnover
- 5,473,669
- Open
- 29.91
- Day Range
- 29.91 - 30.30
- VWAP
- 30.09
- Prev Close
- 30.10
- Last Trade
- 28/10 4:10pm
Key information
Displays key information on the security, sourced from Morningstar.
- Sector
- Healthcare
- Shares Issued
- 418,716,268
- NTA/Share
- 3.06
- Last Dividend
- 0.31
- Dividend Ex Date
- 2 OCT 2026
- Dividend Pay Date
- 6 NOV 2026
Current (USD) · FY2025
Displays key financial data for the most recent fiscal year, in millions. Note - Per share data is in local currency terms irrespective of reporting currency, and may be different to the stated currency, sourced from Morningstar.
- Revenue
- 6,164.00
- EBITDA
- 1,504.00
- Profit
- 625.00
- Earnings Per Share (EPS)
- 1.43
- Dividend Per Share (DPS)
- 0.78
- Yield %
- 2.64
- Market Cap
- 12,605.71
- Price to Earnings Ratio (P/E)
- 20.49
Estimates (USD) · FY2027
Displays consensus analyst’s estimates for key measures for the next fiscal year, sourced from Morningstar.
- Revenue
- 6,760.33
- EBITDA
- 1,429.89
- Profit
- 885.51
- Earnings Per Share (EPS)
- 2.35
- Dividend Per Share (DPS)
- 0.83
Quantitative rating
Displays Morningstar’s Quantitative Equity Research Rating for the security: a star rating from 1 (overvalued) to 5 (undervalued) from the share price against a fair value estimated by a statistical model of Morningstar’s analyst ratings, with the model’s economic moat, financial health and fair value uncertainty, sourced from Morningstar.
Undervalued
- Economic Moat
- Narrow
- Financial Health
- Moderate
- Uncertainty
- Low
Morningstar Quantitative Rating as of 28 OCT 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Displays Morningstar’s quantitative fair value estimate for the security against the current share price, with the band around it: the five-star price below which the model would rate the stock five stars and the one-star price above which it would rate it one star, sourced from Morningstar.
Five-star price 34.02 Fair value 36.65 One-star price 39.49
Morningstar Quantitative Rating as of 28 OCT 2026.
Quantitative valuation
Displays where the share price sits in Morningstar’s quantitative fair value band, from the five-star price (undervalued) to the one-star price (overvalued), with the fair value estimate, the price to fair value ratio, the model’s valuation label and its uncertainty rating, sourced from Morningstar.
Buy
Sell
- Fair Value
- 36.65
- Price / Fair Value
- 0.82
- Valuation
- Undervalued
- Uncertainty
- Low
Morningstar Quantitative Rating as of 28 OCT 2026. The slider runs from the five-star price (34.02) to the one-star price (39.49).
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
| Ratios |
|---|
| Currency (Price/reporting): USD/USD |
| Exchange Rate: 1.0000 |
Price, volume and trading statistics for the security, sourced from Morningstar.
| Price - closing or last bid | 30.12 |
| Price - 12 month high | 37.09 |
| Price - 12 month low | 26.12 |
| Pricing date | 27 OCT 2026 |
| Volume - avg. trading volume for the last ten days | 1.13 |
| Market capitalization | 12,605.71 |
| 12 Month High price date | 27 FEB 2026 |
| 12 Month Low price date | 2 OCT 2026 |
| Volume - avg. trading volume for the last 3 months | 1.53 |
| Price - 1 Day % Change | 0.07% |
| Price - 13 week price percent change | -7.49% |
| Price - 26 week price percent change | -3.09% |
| Price - 5 Day % Change | 3.04% |
| Price - 52 week price percent change | -17.57% |
| Price - YTD price percent change | -8.95% |
| Price % Change Month To Date | 11.23% |
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
| EPS excluding extraordinary items - most recent fiscal year | 1.432 |
| EPS excluding extraordinary items - trailing 12 month | 1.470 |
| EPS Normalized - most recent fiscal year | 2.025 |
| Revenue/share - most recent fiscal year | 14.121 |
| Revenue/share - trailing 12 month | 14.592 |
| Book value per share - most recent fiscal year | 12.454 |
| Book value per share - most recent quarter | 12.266 |
| Book value (tangible) per share - most recent fiscal year | 3.059 |
| Book value (tangible) per share - most recent quarter | 1.977 |
| Cash per share - most recent fiscal year | 1.312 |
| Cash per share - most recent quarter | 1.785 |
| Cash Flow per share - most recent fiscal year | 2.653 |
| Cash Flow per share - trailing 12 month | 2.847 |
| Dividend per share - most recent fiscal year | 0.782 |
| Dividends per share - trailing 12 month | 0.794 |
| EBITD per share - trailing 12 month | 3.542 |
| EPS Basic excluding extraordinary items - most recent fiscal year | 1.442 |
| EPS Basic excluding extraordinary items - trailing 12 month | 1.484 |
| EPS including extraordinary items - most recent fiscal year | 1.442 |
| EPS including extraordinary items - trailing 12 month | 1.484 |
| Free Cash Flow per share - trailing 12 month | 1.726 |
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
| P/E excluding extraordinary items, most recent fiscal year | 20.49 |
| P/E Normalized, most recent fiscal year | 14.26 |
| Price to sales - most recent fiscal year | 2.06 |
| Price to Tangible Book - most fiscal year | 15.23 |
| Price to Free Cash Flow per Share - most recent fiscal year | 17.45 |
| Price to Cash Flow per share - trailing 12 month | 10.58 |
| Price to Book - most recent fiscal year | 2.46 |
| P/E excluding extraordinary items high, trailing 12 months | 33.17 |
| P/E excluding extraordinary items low, trailing 12 months | 17.97 |
| Net Debt, LFI | 3,031.00 |
| Net Debt, LFY | 2,770.00 |
| Dividend Yield - 5 Year Average | 2.57% |
| Dividend Yield - indicated annual dividend divided by closing price | 2.64% |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 2.64% |
Cash flow, liquidity and leverage measures, sourced from Morningstar.
| Free Cash Flow - most recent fiscal year | 725.00 |
| LT debt/equity - most recent fiscal year | 60.07% |
| Payout ratio - most recent fiscal year | 54.61% |
| Total debt/total equity - most recent fiscal year | 62.90% |
| LT debt/equity - most recent quarter | 62.01% |
| Total debt/total equity - most recent quarter | 73.07% |
| Free Cash Flow - trailing 12 month | 745.00 |
| Payout ratio - trailing 12 month | 54.01% |
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
| Revenue - most recent fiscal year | 6,164.00 |
| Revenue - trailing 12 month | 6,300.00 |
| EBITD - most recent fiscal year | 1,504.00 |
| EBITD - trailing 12 month | 1,529.00 |
| Earnings before taxes - most recent fiscal year | 779.00 |
| Earnings before taxes - trailing 12 month | 797.00 |
| Net Income available to common - most recent fiscal year | 625.00 |
| Net Income available to common - trailing 12 months | 635.00 |
| Earnings before taxes Normalized - most recent fiscal year | 1,086.00 |
| Net Income Available to Common, Normalized - most recent fiscal year | 884.00 |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | 2.11 |
Profitability margins for the most recent fiscal year, sourced from Morningstar.
| Net Profit Margin % - 1st historical fiscal year | 10.14% |
| Net Profit Margin % - trailing 12 month | 10.08% |
| Operating margin - 1st historical fiscal year | 13.90% |
| Operating margin - trailing 12 month | 13.90% |
| Pretax margin - trailing 12 month | 12.65% |
| Pretax margin - 1st historical fiscal year | 12.64% |
| Operating Margin - 5 year average | 13.02% |
| Pretax Margin - 5 year average | 8.44% |
| Free Operating Cash Flow/Revenue, 5 Year Average | 11.69% |
| Free Operating Cash Flow/Revenue, TTM | 11.83% |
| Net Profit Margin - 5 year average | 7.26% |
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
| Return on average assets - most recent fiscal year | 5.95% |
| Return on average assets - trailing 12 month | 5.92% |
| Return on average equity - most recent fiscal year | 11.65% |
| Return on average equity - trailing 12 month | 11.90% |
| Return on average assets - 5 year average | 4.00% |
| Return on average equity - 5 year average | 7.86% |
| Net Income/employee - most recent fiscal year | 36,790.68 |
| Revenue/employee - most recent fiscal year | 362,844.36 |
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
| Revenue growth rate, 5 year | 6.21% |
| EPS growth rate, 5 year | 6.94% |
| Growth rate% - dividend, 3 year | 0.53% |
| Revenue/share (5 yr growth) | 6.31% |
| Growth rate% - Revenue, 3 year | 5.73% |
| Growth rate% - EPS, 3 year | 41.08% |
| Book value per share growth rate, 5 year | 0.68% |
| Capital Spending growth rate, 5 year | -0.46% |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | 11.83% |
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.
Financial forecast (USD, millions except per share)
| Actuals | Estimates | |||||||
| 2025 | 2026 | 2027 | 2028 | 2029 | ||||
| Estimate breakdown | ||||||||
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.
Financials (USD, millions)
| Period end: | DEC 21 | DEC 22 | DEC 23 | DEC 24 | DEC 25 |
| Fiscal year: | 2021 | 2022 | 2023 | 2024 | 2025 |
| Period length: | 12 months | 12 months | 12 months | 12 months | 12 months |
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.
Business Summary
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
